晚期前列腺癌的内分泌治疗现状
-
摘要: 前列腺癌是欧美国家男性最常见的恶性肿瘤,也是全球男性继肺癌之后位居第二位的恶性肿瘤。其发病率在全球范围内呈上升趋势,近年来尽管联合应用经直肠指检、血(PSA)、经直肠超声检查、前列腺穿刺等手段使早期前列腺癌检出率大大提高,但由于我国目前尚未普及前列腺癌筛查,80%~90%的患者在确诊时已伴有远处转移,只能接受姑息性内分泌治疗。
-
[2] 马春光,叶定伟,李长岭,等.前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J].中华外科杂志2008,46 (12 ):921-925. [2] Peyrornaure M,Debre B,Mao K,et al.Management of prostate cancer in China: a multicenter report of 6 institutions[J].J Urol,2005,174(5):1794 - 1797. [3] Higgins GS,McLaren DB,Kerr GR,et al.Outcome analysis of 300prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,65(4):982. [4] Oh WK.The evolving role of estrogen therapy in prostate cancer[J]. Clin Prostate Cancer,2002,1(2):81-89. [5] Labrie F,Be1anger A,Luu-The V,et al.Gonadotropin-releasing hormone agonists in the treatment of prostate cancer[J].Endoer Rev,2005,26(3):361-379. [6] Yri OE,Bjoro T,Fossa SD. Failure to achieve castration levels inpatients using leuprolide acetate in locally advanced prostatecancer[J].Eur Urol,2006,49(1):54-58. [7] Weston P,Persson BE.Re: Weckermann D,Harzmann R.Hormone therapy in prostate cancer:LHRH antagonists versus LHRHanalogues[J]. Eur Urol,2004,46(3):279-284. [8] AKaza H,Hinotsu S,Usami M,et al.Combined androgen blockadewith bicalutamide for advanced prostate cancer:long-term followupof a phase 3,double-blind,randomized study for survival[J].Cancer,2009,115(15):3437-3445. [9] Schellhammer PF,Davis JW.An evaluation of bicalutamide in thetreatment of prostate cancerl[J]. Clin Prostate Cancer,2004,2(4):213-219. [10] Geller J,Albert J.Comparison of prostatic cancer tissue dihydrotestosterone level sat the time of rdaple following orchieetomyo restrogen therap[J].J Urol,1984,132(4):693-696. [11] Laurence K,Koichiro A,David G,et al.Advanced prostatecancer: hormones and beyond[J].Eur Urol Suppl,2007,6(3):354-364. [12] Fernand L,Bernard C. Maximum androgen blocked in advancedprostate cancer: an overview of the randomized trials[J]. Lancet,2000, 355( 9214):1491-1498. [13] 黄海,许可慰,黄健等.晚期前列腺癌内分泌治疗药物的疗效观察[J].中华泌尿外科杂志,2010,31(1). 45-48. [14] K1otz L,Schellhammer P,Carroll K.A reassessment of the role ofcombined androgen blockade for advanced prostate cancer[J].BJU Int,2 O04, 93(9):1177-1182. [15] Iversen P,Tyrrell CJ,Kaisary AV, et al.Bicalutamide monotherapycompared with castration in patients with nonmetastatic locallyadvanced prostate cancer: 6.3 years of followup[J].J Urol, 2000,164(5):1579-1582. [16] Tannock IF,De Wit R,Berry WR,et al.Docetaxel plus prednisoneor mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med, 2004,351(15):1502-1512. [17] Miyake H,Hara I,Eto H. Clinical outcome of maximum androgenblockade using flutamind as second-line hormonal therapy forhormone-refractory prostat cancer[J].BJU Int,2005,96 (6):791-795. [18] Klotz L. Maximal androgen blockade for advanced prostate cancer[J].Best Pract Res Clin Endocrinol Metab,2008,22(2):331 -340. [19] Penson DF,Ramsey S,Veenatra D,et al. the cost-effectiveness ofcombined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostatecancer[J].J Urol, 2005,174(2):547-552. [20] 那彦群,孙光,叶章群等.中国泌尿外科疾病诊断治疗指南:2009 版[M].北京: 人民卫生出版社,2009:39-59. [21] Studer UE,Hauri D,Hanselmann S,et al.Immediate versusdeferred hormonal treatment for patients with prostate cancer whoare not suitable for curative local treatment: results of therandomized trial SAKK08/88[J]. J Clin Onco1,2004,22( 20):4109 - 4118. [22] [22 Goldenberg SL,Bruchovsdy N,Gleave ME,et al. Intermittent androgen suppression in the treatment of prostate cancer,A preliminary report[J].Urology,1995,45( 5):839-845. [23] Da Silva FC,Bono A,Whdan P,et al.Phase III study of intermittent MAB versus continuous MAB-an internationalcooperative study[J].Eur Urol,2006,5(4):289-291. [24] Kaneko Y,Maekawa S,Arakaki R,et al.Intermittent androgendeprivation therapy may prolong the duration of androgen dependence of well differentiated prostate cancer[J].HinyokikaKiyo,2006,52(4):259-264.
点击查看大图
计量
- 文章访问数: 3416
- HTML全文浏览量: 343
- PDF下载量: 353
- 被引次数: 0